Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Other Admin

Neurothera Labs Engages bullVestor for Investor Relations Activities

By The Northwire Desk — AI Analysis Apr 23, 2026 · 18:00 NTLX · 0.16 NeuroThera Labs Inc.
NTLX · Price

Executive Summary

  • Neurothera Labs Inc. has entered into an agreement with bullVestor Median GmbH to conduct an investor awareness marketing campaign.
  • The engagement is subject to approval by the TSX Venture Exchange (TSXV).
  • The contract covers a 6-month period with a total cost of €300,000.

Key Details

  • Service Provider: bullVestor Median GmbH (based in Austria).
  • Scope of Services: Content creation management, keyword optimization, ad groups and display ads, project management, and media distribution.
  • Total Contract Value: €300,000 for a 6-month period.
  • Payment Schedule:
    • €150,000 payable within seven days following TSXV approval of the engagement.
    • Remaining €150,000 payable within 45 days following TSXV approval.
  • Regulatory Condition: The engagement is subject to the approval of the TSX Venture Exchange (TSXV).
Read the original news release →

More from NeuroThera Labs Inc.

Jun 30, 2026 · 18:00

Pre-revenue neurology and cannabis-tech company raises capital at a discount to fund operations and settle parent company debt.

Financings Jun 03, 2026 · 17:15

Neurothera Closes Cashless Quantum-Tech Acquisition, But Dilution and Clinical Stage Risks Keep Upside Capped

M&A / Property May 27, 2026 · 08:00

Neurothera Labs Confirms Acquisition Closing Amidst Significant Equity Dilution and Regulatory Scrutiny

M&A / Property May 20, 2026 · 17:00

Neurothera Labs Announces Adoption of Semi-Annual Reporting

Other Apr 30, 2026 · 10:59

Neurothera Labs Announces Continuance into Ontario

Other Mar 16, 2026 · 07:31

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

M&A / Property